Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Milvexian

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program

    25 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230524005933/en

    BUSINESSWIRE
    25 May 2023
    Share Share
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications

    25 May 2023

    // PRESS RELEASE

    https://johnsonandjohnson.gcs-web.com/static-files/4120e707-3112-4f0b-a1d2-7015893e855c

    PRESS RELEASE
    25 May 2023
    Share Share
    BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian
    BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian

    03 Mar 2023

    // PRESS RELEASE

    https://news.bms.com/news/details/2023/The-Bristol-Myers-Squibb-Janssen-Collaboration-Launches-Pivotal-Phase-3-Librexia-Clinical-Trial-Program-Evaluating-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor/default.aspx

    PRESS RELEASE
    03 Mar 2023
    Share Share
    The BMS-Janssen Collaboration Launches PIII Trial Evaluating Milvexian
    The BMS-Janssen Collaboration Launches PIII Trial Evaluating Milvexian

    02 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230228006466/en

    BUSINESSWIRE
    02 Mar 2023
    Share Share
    Results From PII Study of Milvexian Show Favorable Antithrombotic Profile
    Results From PII Study of Milvexian Show Favorable Antithrombotic Profile

    28 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220827005002/en

    BUSINESSWIRE
    28 Aug 2022
    Share Share
    New J&J CEO Duato points out 5 promising pipeline meds
    New J&J CEO Duato points out 5 promising pipeline meds

    11 Jan 2022

    // E. Sagonowsky FIERCEPHARMA

    https://www.fiercepharma.com/pharma/johnson-johnson-ceo-duato-points-out-5-pipeline-meds-can-generate-5b

    E. Sagonowsky FIERCEPHARMA
    11 Jan 2022
    Share Share